Answers are grounded in this paper and cite their sources.
You have accessJournal of UrologySexual Function/Dysfunction: Peyronie's Disease (MP28)1 May 2024MP28-19 A SURVEY OF EXPOSURE TO THE USE OF XIAFLEX FOR THE TREATMENT OF PEYRONIE'S DISEASE AMONG UNITED STATES UROLOGY RESIDENCY PROGRAMS Justin Loloi, Kyle Schuppe, Raghuram V. Reddy, Farah Rahman, Ari Bernstein, Pritika Reddy, Nikhil Kulkarni, Thomas Masterson, and Ranjith Ramasamy Justin LoloiJustin Loloi , Kyle SchuppeKyle Schuppe , Raghuram V. ReddyRaghuram V. Reddy , Farah RahmanFarah Rahman , Ari BernsteinAri Bernstein , Pritika ReddyPritika Reddy , Nikhil KulkarniNikhil Kulkarni , Thomas MastersonThomas Masterson , and Ranjith RamasamyRanjith Ramasamy View All Author Informationhttps://doi.org/10.1097/01.JU.0001008872.42208.7a.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Xiaflex® (Collagenase Clostridium Histolyticum) is an FDA-approved treatment for patients with Peyronie's Disease. Despite its approval and widespread implementation in clinical practice, there is concern that urologists in training are offered minimal exposure to its use. Thus, the purpose of this study was to evaluate the exposure of urology residents to Peyronie's Disease and its management, particularly Xiaflex®. METHODS: A three-question Google Forms survey regarding exposure of residents to Peyronie's Disease and the Use of Xiaflex® was created and disseminated through email to urology residency programs. RESULTS: Overall, 47 institutional responses were received (34% response rate). At 45 institutions (96%), residents receive training in directly caring for patients with Peyronie's disease. At 46 institutions (98%), residents receive training in observing and/or performing surgical procedures for Peyronie's disease. Conversely, residents at only 31 institutions (66%) receive observational or procedural training for non-surgical management of Peyronie's disease, specifically Xiaflex®. Residents receive non-surgical training by an academic faculty who is fellowship trained in sexual medicine at 25 institutions and an academic faculty who is not trained in sexual medicine at 6 institutions. CONCLUSIONS: To our knowledge, we present the first study evaluating resident exposure to Xiaflex® in the treatment of PD. Despite widespread exposure to the surgical treatment of PD, there exists a glaring disparity in residency exposure to Xiaflex®. A broader incorporation of training of Xiaflex® among urology residents may increase the number of providers who are comfortable and competent with providing this level of care. Download PPTDownload PPTDownload PPT Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e479 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Justin Loloi More articles by this author Kyle Schuppe More articles by this author Raghuram V. Reddy More articles by this author Farah Rahman More articles by this author Ari Bernstein More articles by this author Pritika Reddy More articles by this author Nikhil Kulkarni More articles by this author Thomas Masterson More articles by this author Ranjith Ramasamy More articles by this author Expand All Advertisement PDF downloadLoading ...
No takes yet. Share an insight, caveat, or question.
Loloi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: